Inflarx (NASDAQ:IFRX) posted its quarterly earnings results on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.20, MarketWatch Earnings reports.
Shares of IFRX stock traded up $0.02 on Friday, hitting $8.62. The company’s stock had a trading volume of 3,302 shares, compared to its average volume of 910,728. The stock’s 50 day moving average is $6.13 and its 200-day moving average is $4.16. Inflarx has a fifty-two week low of $2.17 and a fifty-two week high of $42.99. The company has a market capitalization of $208.32 million, a PE ratio of -3.68 and a beta of 0.53.
Several equities analysts have recently weighed in on IFRX shares. Raymond James increased their price objective on shares of Inflarx from $10.00 to $20.00 and gave the company an “outperform” rating in a research report on Thursday. SVB Leerink increased their price objective on shares of Inflarx from $4.00 to $7.00 and gave the company a “hold” rating in a research report on Thursday, May 7th. BMO Capital Markets increased their price objective on shares of Inflarx from $4.00 to $7.00 and gave the company a “market perform” rating in a research report on Thursday. Finally, ValuEngine raised shares of Inflarx from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Two research analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Inflarx currently has an average rating of “Hold” and an average price target of $8.00.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.